Late response to low-dose imatinib in patients with chronic phase chronic myeloid leukemia

详细信息    查看全文

• 作者：Akiyoshi Takami (1)
  Shigeki Ohtake (1)
  Eriko Morishita (1)
  Yasushi Terasaki (2)
  Toshihiro Fukushima (3)
  Toshiro Kurokawa (4)
  Naomi Sugimori (1)
  Sadaya Matano (5)
  Kinya Ohata (1)
  Chizuru Saito (1)
  Masaki Yamaguchi (6)
  Kohei Hosokawa (1)
  Hirohito Yamazaki (1)
  Yukio Kondo (1)
  Shinji Nakao (1)
  
• 关键词：Chronic myeloid leukemia ; Imatinib ; Late response ; Molecular response
• 刊名：International Journal of Hematology
• 出版年：2012
• 出版时间：September 2012
• 年：2012
• 卷：96
• 期：3
• 页码：357-363
• 全文大小：230KB
• 参考文献：1. Deininger MWN, O’Brien SG, Ford JM, Druker BJ. Practical management of patients with chronic myeloid leukemia receiving imatinib. J Clin Oncol. 2003;21(8):1637-7. CrossRef
  2. Druker BJ, Talpaz M, Resta DJ, Peng B, Buchdunger E, Ford JM, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med. 2001;344(14):1031-. CrossRef
  3. Druker BJ, Tamura S, Buchdunger E, Ohno S, Segal GM, Fanning S, et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med. 1996;2(5):561-. CrossRef
  4. Deininger MWN, Goldman JM, Lydon N, Melo JV. The tyrosine kinase inhibitor CGP57148B selectively inhibits the growth of bcr-abl–positive cells. Blood. 1997;90(9):3691-.
  5. O’Brien SG, Guilhot F, Goldman JM, Hochhaus A, Hughes TP, Radich JP, et al. International randomized study of interferon versus STI571 (IRIS) 7-year follow-up: sustained survival, low rate of transformation and increased rate of major molecular response (MMR) in patients (pts) with newly diagnosed chronic myeloid leukemia in chronic phase (CMLCP) treated with imatinib (IM). ASH Annual Meeting Abstracts 2008;112(11):186.
  6. Kanda Y, Okamoto S, Tauchi T, Kizaki M, Inokuchi K, Yabe M, et al. Multicenter prospective trial evaluating the tolerability of imatinib for Japanese patients with chronic myelogenous leukemia in the chronic phase: does body weight matter? Am J Hematol. 2008;83(11):835-. CrossRef
  7. Morishima Y, Ogura M, Nishimura M, Yazaki F, Bessho M, Mizoguchi H, et al. Efficacy and safety of imatinib mesylate for patients in the first chronic phase of chronic myeloid leukemia: results of a Japanese phase II clinical study. Int J Hematol. 2004;80(3):261-. CrossRef
  8. Cortes J, Talpaz M, O’Brien S, Giles F, Beth Rios M, Shan J, et al. Effects of age on prognosis with imatinib mesylate therapy for patients with Philadelphia chromosome-positive chronic myelogenous leukemia. Cancer. 2003;98(6):1105-3. CrossRef
  9. Harrison SJ, Johnson PRE, Holyoake TL. The Scotland Leukaemia Registry audit of incidence, diagnosis and clinical management of new patients with chronic myeloid leukaemia in 1999 and 2000. Scott Med J. 2004;49(3):87-0.
  10. Michor F, Iwasa Y, Nowak MA. The age incidence of chronic myeloid leukemia can be explained by a one-mutation model. Proc Nat Acad Sci USA. 2006;103(40):14931-. CrossRef
  11. Hehlmann R, Hochhaus A, Baccarani M. Chronic myeloid leukaemia. Lancet. 2007;370(9584):342-0. CrossRef
  12. Matsuo K, Ito H. Descriptive epidemiology of myeloid leukemia. Nihon Rinsho. 2009;67(10):1847-1.
  13. Breccia M, Tiribelli M, Alimena G. Tyrosine kinase inhibitors for elderly chronic myeloid leukemia patients: a systematic review of efficacy and safety data. Crit Rev Oncol Hematol. 2012
  14. Saglio G, Kim D-W, Issaragrisil S, le Coutre P, Etienne G, Lobo C, et al. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med. 2010;362(24):2251-. CrossRef
  15. Kantarjian H, Shah NP, Hochhaus A, Cortes J, Shah S, Ayala M, et al. Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 2010;362(24):2260-0. CrossRef
  16. Breccia M, Cannella L, Stefanizzi C, Latagliata R, Nanni M, Diverio D, et al. Cytogenetic and molecular responses in chronic phase chronic myeloid leukaemia patients receiving low dose of imatinib for intolerance to standard dose. Hematol Oncol. 2010;28(2):89-2.
  17. Carella AM, Lerma E. Durable responses in chronic myeloid leukemia patients maintained with lower doses of imatinib mesylate after achieving molecular remission. Ann Hematol. 2007;86(10):749-2. CrossRef
  18. Kobayashi S, Kimura F, Kobayashi A, Sato K, Motoyoshi K. Efficacy of low-dose imatinib in chronic-phase chronic myelogenous leukemia patients. Ann Hematol. 2009;88(4):311-. CrossRef
  19. Park SJ, Choi IK, Seo HY, Sung HJ, Park KH, Kim SJ, et al. Reduced dose of imatinib for patients with chronic myeloid leukemia and low body surface area. Acta Haematol. 2007;118(4):219-1. CrossRef
  20. Horikoshi A, Takei K, Sawada S. Effects of lower dose of imatinib to CML patients. Leuk Res. 2003;27(12):1167. CrossRef
  21. Horikoshi A, Takei K, Sawada S. Relationship between daily dose of imatinib per square meter and its plasma concentration in patients with chronic-phase chronic myeloid leukemia (CML). Leuk Res. 2007;31(4):574-. CrossRef
  22. Yoshida C, Komeno T, Hori M, Kimura T, Fujii M, Okoshi Y, et al. Adherence to the standard dose of imatinib, rather than dose adjustment based on its plasma concentration, is critical to achieve a deep molecular response in patients with chronic myeloid leukemia. Int J Hematol. 2011;93(5):618-3. CrossRef
  23. Baccarani M, Cortes J, Pane F, Niederwieser D, Saglio G, Apperley J, et al. Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. J Clin Oncol. 2009;27(35):6041-1. CrossRef
  24. Yagasaki F, Niwa T, Abe A, Ishikawa M, Kato C, Ogura K, et al. Correlation of quantification of major bcr-abl mRNA between TMA (transcription mediated amplification) method and real-time quantitative PCR. Rinsho Ketsueki. 2009;50(6):481-.
  25. Langabeer SE, Gale RE, Harvey RC, Cook RW, Mackinnon S, Linch DC. Transcription-mediated amplification and hybridisation protection assay to determine BCR-ABL transcript levels in patients with chronic myeloid leukaemia. Leukemia. 2002;16(3):393-. CrossRef
  26. Sumi M, Tauchi T, Sashida G, Shoji N, Gotoh A, Itoh Y, et al. Clinical usefulness of transcription-mediated amplification and hybridization protection assay in imatinib-treated chronic myelogenous leukemia patients. Clin Lab Haematol. 2005;27(6):416-. CrossRef
  27. Takahashi N, Kyo T, Maeda Y, Sugihara T, Usuki K, Kawaguchi T, et al. Discontinuation of imatinib in Japanese patients with chronic myeloid leukemia. Haematologica. 2012;97(6):903-. CrossRef
  28. Kanda Y. EZR (Easy R) on R commander. http://wwwjichiacjp/saitama-sct/SaitamaHPfiles/statmedENhtml. Accessed 1 April 2012.
  29. Nakamae H, Shibayama H, Kurokawa M, Fukuda T, Nakaseko C, Kanda Y, et al. Nilotinib as frontline therapy for patients with newly diagnosed Ph?+?chronic myeloid leukemia in chronic phase: results from the Japanese subgroup of ENESTnd. Int J Hematol. 2011;93(5):624-2. CrossRef
  30. Kantarjian H, Sawyers C, Hochhaus A, Guilhot F, Schiffer C, Gambacorti-Passerini C, et al. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med. 2002;346(9):645-2. CrossRef
  31. Jabbour E, Cortes JE, Kantarjian HM. Suboptimal response to or failure of imatinib treatment for chronic myeloid leukemia: what is the optimal strategy? Mayo Clin Proc. 2009;84(2):161-. CrossRef
  32. Mauro MJ, Lipton JH, Miller CB, Ailawadhi S, Busque L, Akard LP, et al. Analysis of imatinib (IM)-related, low-grade (LG), non-hematologic (heme) adverse events (AEs) in patients (pts) with chronic myeloid leukemia (CML) switched to nilotinib (NIL): ENRICH study update. ASCO Meeting Abstracts. 2012;30(15 suppl):6605
  33. Latagliata R, Breccia M, Carmosino I, Sarlo C, Montefusco E, Mancini M, et al. Elderly patients with Ph?+?chronic myelogenous leukemia (CML): results of imatinib mesylate treatment. Leuk Res. 2005;29(3):287-1. CrossRef
  34. Rosti G, Iacobucci I, Bassi S, Castagnetti F, Amabile M, Cilloni D, et al. Impact of age on the outcome of patients with chronic myeloid leukemia in late chronic phase: results of a phase II study of the GIMEMA CML Working Party. Haematologica. 2007;92(1):101-. CrossRef
  35. Latagliata R, Breccia M, Carmosino I, Cannella L, De Cuia R, Diverio D, et al. “Real-life-results of front-line treatment with Imatinib in older patients (>/=?65?years) with newly diagnosed chronic myelogenous leukemia. Leuk Res. 2010;34(11):1472-. CrossRef
  36. Pletsch N, Lauseker M, Saussele S, Leitner A, Jung-Munkwitz S, Müller MC, et al. Therapy with imatinib in elderly CML patients (?5?years) is well tolerated but cytogenetic and molecular remissions seem to be achieved later compared to younger patients. Haematologica. 2009;94(suppl 2):253 (abst 0625).
  37. Gugliotta G, Castagnetti F, Palandri F, Breccia M, Intermesoli T, Capucci A, et al. Frontline imatinib treatment of chronic myeloid leukemia: no impact of age on outcome, a survey by the GIMEMA CML Working Party. Blood. 2011;117(21):5591-. CrossRef
  38. Ohnishi K, Nakaseko C, Takeuchi J, Fujisawa S, Nagai T, Yamazaki H, et al. Long-term outcome following imatinib therapy for chronic myelogenous leukemia, with assessment of dosage and blood levels: the JALSG CML202 study. Cancer Sci. 2012;103(6):1071-. CrossRef
  39. Michor F, Hughes TP, Iwasa Y, Branford S, Shah NP, Sawyers CL, et al. Dynamics of chronic myeloid leukaemia. Nature. 2005;435(7046):1267-0. CrossRef
  40. Roeder I, Horn M, Glauche I, Hochhaus A, Mueller MC, Loeffler M. Dynamic modeling of imatinib-treated chronic myeloid leukemia: functional insights and clinical implications. Nat Med. 2006;12(10):1181-. CrossRef
  41. Komarova NL, Wodarz D. Drug resistance in cancer: principles of emergence and prevention. Proc Natl Acad Sci USA. 2005;102(27):9714-. CrossRef
  
• 作者单位：Akiyoshi Takami (1)
  Shigeki Ohtake (1)
  Eriko Morishita (1)
  Yasushi Terasaki (2)
  Toshihiro Fukushima (3)
  Toshiro Kurokawa (4)
  Naomi Sugimori (1)
  Sadaya Matano (5)
  Kinya Ohata (1)
  Chizuru Saito (1)
  Masaki Yamaguchi (6)
  Kohei Hosokawa (1)
  Hirohito Yamazaki (1)
  Yukio Kondo (1)
  Shinji Nakao (1)
  
  1. Department of Hematology and Oncology, Kanazawa University Hospital, 13-1 Takaramachi, Kanazawa, 920-8641, Japan
  2. Department of Internal Medicine, Toyama City Hospital, Toyama, Japan
  3. Department of Hematology and Immunology, Kanazawa Medical University, Kahoku, Japan
  4. Department of Hematology, Toyama Red Cross Hospital, Toyama, Japan
  5. Department of Hematology, Tonami General Hospital, Tonami, Japan
  6. Department of Hematology, Ishikawa Prefectural Central Hospital, Kanazawa, Japan
  

文摘

Imatinib was the first BCR-ABL tyrosine kinase inhibitor to become clinically available. In this study, we retrospectively evaluated the long-term efficacy of low-dose imatinib (final maintenance dose <300?mg per day) due to intolerance, in comparison to optimal-dose imatinib (?00?mg per day) in patients with Philadelphia chromosome-positive chronic myeloid leukemia in the chronic phase. The Kaplan–Meier estimates of the median time to complete cytogenetic response, major molecular response, and complete molecular response were longer for 31 patients receiving low-dose imatinib (360, 1360, and 1420?days, respectively) than 74 patients receiving optimal-dose imatinib (170, 420, and 720?days, respectively). However, the differences in response shrank over time and progression-free survival were comparable between the two groups. These findings suggest that long-term treatment with low-dose imatinib is an acceptable alternative for patients with intolerance to the optimal dose.